Skip to main content
Erschienen in: Acta Neurochirurgica 2/2014

01.02.2014 | Clinical Article - Brain Tumors

Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma

verfasst von: Maria Angela Samis Zella, Marta Wallocha, Philipp J. Slotty, Gueler Isik, Daniel Hänggi, Juliane Schroeteler, Christian Ewelt, Hans-Jakob Steiger, Michael Sabel

Erschienen in: Acta Neurochirurgica | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Patients with glioblastoma treated with BCNU wafer implantation for recurrence frequently receive frontline chemoradiotherapy with temozolomide as part of the Stupp protocol. A retrospective investigation was conducted of surgical complications in a cohort of these patients treated at a single institution.

Methods

We searched our institutional database for patients treated between January 2006 and October 2012 who had recurrent glioblastoma previously treated with open surgery followed by the Stupp protocol and then underwent repeat resection with or without BCNU wafers for recurrent disease. Rates of select post-operative complications within 3 months of surgery were estimated.

Results

We identified 95 patients with glioblastoma who underwent resection followed by the Stupp protocol as frontline treatment. At disease recurrence (first and second recurrence), 63 patients underwent repeat resection with BCNU wafer implantation and 32 without implantation. Generally, BCNU wafer use was associated with minor to moderate increases in rates of select complications versus non-implantation—wound healing abnormalities (14.2 vs. 6.2 %), cerebrospinal fluid leak (7.9 vs. 3.1 %), hydrocephalus requiring ventriculoperitoneal shunt (6.3 vs. 9.3 %), chemical meningitis (3.1 vs. 0 %), cerebral infections (3.1 vs. 0 %), cyst formation (3.1 vs. 3.1 %), cerebral edema (4.7 vs. 0 %), and empyema formations (1.5 vs. 0 %). Performance status was well maintained post-operatively in both groups. Median progression-free survival from the time of first recurrence was 6.0 and 5.0 months, respectively.

Conclusions

The use of the Stupp protocol as frontline therapy in patients with glioblastoma does not preclude the use of BCNU wafers at the time of progression.
Literatur
1.
Zurück zum Zitat Attenello FJ, Mukherjee D, Datoo G, McGirt MJ, Bohan E, Weingart JD, Olivi A, Quinones-Hinojosa A, Brem H (2008) Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 15:2887–2893PubMedCrossRef Attenello FJ, Mukherjee D, Datoo G, McGirt MJ, Bohan E, Weingart JD, Olivi A, Quinones-Hinojosa A, Brem H (2008) Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 15:2887–2893PubMedCrossRef
2.
Zurück zum Zitat Balmaceda C, Peereboom D, Pannullo S, Cheung YK, Fisher PG, Alavi J, Sisti M, Chen J, Fine RL (2008) Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer 112:1139–1146PubMedCrossRef Balmaceda C, Peereboom D, Pannullo S, Cheung YK, Fisher PG, Alavi J, Sisti M, Chen J, Fine RL (2008) Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer 112:1139–1146PubMedCrossRef
3.
Zurück zum Zitat Balossier A, Dorner L, Emery E, Heese O, Mehdorn HM, Menei P, Singh J (2010) Incorporating BCNU wafers into malignant glioma treatment: European case studies. Clin Drug Investig 30:195–204PubMedCrossRef Balossier A, Dorner L, Emery E, Heese O, Mehdorn HM, Menei P, Singh J (2010) Incorporating BCNU wafers into malignant glioma treatment: European case studies. Clin Drug Investig 30:195–204PubMedCrossRef
4.
Zurück zum Zitat Barker FG 2nd (1994) Efficacy of prophylactic antibiotics for craniotomy: a meta-analysis. Neurosurgery 35:484–490PubMedCrossRef Barker FG 2nd (1994) Efficacy of prophylactic antibiotics for craniotomy: a meta-analysis. Neurosurgery 35:484–490PubMedCrossRef
5.
Zurück zum Zitat Barker FG 2nd (2007) Efficacy of prophylactic antibiotics against meningitis after craniotomy: a meta-analysis. Neurosurgery 60:887–894PubMedCrossRef Barker FG 2nd (2007) Efficacy of prophylactic antibiotics against meningitis after craniotomy: a meta-analysis. Neurosurgery 60:887–894PubMedCrossRef
6.
Zurück zum Zitat Bock HC, Cohnen J, Keric N, Kantelhardt SR, Giese A (2011) Occlusion of surgical opening of the ventricular system with fibrinogen-coated collagen fleece: a case collection study. Acta Neurochir (Wien) 153:533–539CrossRef Bock HC, Cohnen J, Keric N, Kantelhardt SR, Giese A (2011) Occlusion of surgical opening of the ventricular system with fibrinogen-coated collagen fleece: a case collection study. Acta Neurochir (Wien) 153:533–539CrossRef
7.
Zurück zum Zitat Bock HC, Puchner MJ, Lohmann F, Schutze M, Koll S, Ketter R, Buchalla R, Rainov N, Kantelhardt SR, Rohde V, Giese A (2010) First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurg Rev 33:441–449PubMedCentralPubMedCrossRef Bock HC, Puchner MJ, Lohmann F, Schutze M, Koll S, Ketter R, Buchalla R, Rainov N, Kantelhardt SR, Rohde V, Giese A (2010) First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurg Rev 33:441–449PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Schold SC (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet 345:1008–1012PubMedCrossRef Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Schold SC (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet 345:1008–1012PubMedCrossRef
9.
Zurück zum Zitat Della Puppa A, Rossetto M, Ciccarino P, Denaro L, Rotilio A, d'Avella D, Scienza R (2011) Carmustine wafer implantation when surgical cavity is communicating with cerebral ventricles: technical considerations on a clinical series. World Neurosurg 76:156–159PubMedCrossRef Della Puppa A, Rossetto M, Ciccarino P, Denaro L, Rotilio A, d'Avella D, Scienza R (2011) Carmustine wafer implantation when surgical cavity is communicating with cerebral ventricles: technical considerations on a clinical series. World Neurosurg 76:156–159PubMedCrossRef
10.
Zurück zum Zitat Deorah S, Lynch CF, Sibenaller ZA, Ryken TC (2006) Trends in brain cancer incidence and survival in the United States: surveillance, epidemiology, and end results program, 1973 to 2001. Neurosurg Focus 20:E1PubMedCrossRef Deorah S, Lynch CF, Sibenaller ZA, Ryken TC (2006) Trends in brain cancer incidence and survival in the United States: surveillance, epidemiology, and end results program, 1973 to 2001. Neurosurg Focus 20:E1PubMedCrossRef
11.
Zurück zum Zitat Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213PubMedCrossRef Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213PubMedCrossRef
12.
Zurück zum Zitat Dixit S, Hingorani M, Achawal S, Scott I (2011) The sequential use of carmustine wafers (Gliadel(R)) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review. Br J Neurosurg 25:459–469PubMedCrossRef Dixit S, Hingorani M, Achawal S, Scott I (2011) The sequential use of carmustine wafers (Gliadel(R)) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review. Br J Neurosurg 25:459–469PubMedCrossRef
13.
Zurück zum Zitat Engelhard HH (2000) Tumor bed cyst formation after BCNU wafer implantation: report of two cases. Surg Neurol 53:220–224PubMedCrossRef Engelhard HH (2000) Tumor bed cyst formation after BCNU wafer implantation: report of two cases. Surg Neurol 53:220–224PubMedCrossRef
14.
Zurück zum Zitat Engelhard HH, Maher de Leon M, Rozental J (1998) Tumor bed cyst formation after BCNU wafer implantation. Annual Meeting of the Congress of Neurological Surgeons, Seattle Engelhard HH, Maher de Leon M, Rozental J (1998) Tumor bed cyst formation after BCNU wafer implantation. Annual Meeting of the Congress of Neurological Surgeons, Seattle
15.
Zurück zum Zitat Fadul CE, Wen PY, Kim L, Olson JJ (2008) Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme. J Neurooncol 89:339–357PubMedCrossRef Fadul CE, Wen PY, Kim L, Olson JJ (2008) Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme. J Neurooncol 89:339–357PubMedCrossRef
16.
Zurück zum Zitat Fleming AB, Saltzman WM (2002) Pharmacokinetics of the carmustine implant. Clin Pharmacokinet 41:403–419PubMedCrossRef Fleming AB, Saltzman WM (2002) Pharmacokinetics of the carmustine implant. Clin Pharmacokinet 41:403–419PubMedCrossRef
17.
Zurück zum Zitat Gallego JM, Barcia JA, Barcia-Marino C (2007) Fatal outcome related to carmustine implants in glioblastoma multiforme. Acta Neurochir 149:261–265PubMedCrossRef Gallego JM, Barcia JA, Barcia-Marino C (2007) Fatal outcome related to carmustine implants in glioblastoma multiforme. Acta Neurochir 149:261–265PubMedCrossRef
18.
Zurück zum Zitat Giese A, Bock HC, Kantelhardt SR, Rohde V (2010) Risk management in the treatment of malignant gliomas with BCNU wafer implants. Cen Eur Neurosurg 71:199–206CrossRef Giese A, Bock HC, Kantelhardt SR, Rohde V (2010) Risk management in the treatment of malignant gliomas with BCNU wafer implants. Cen Eur Neurosurg 71:199–206CrossRef
19.
Zurück zum Zitat Giese A, Kucinski T, Knopp U, Goldbrunner R, Hamel W, Mehdorn HM, Tonn JC, Hilt D, Westphal M (2004) Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma. J Neurooncol 66:351–360PubMedCrossRef Giese A, Kucinski T, Knopp U, Goldbrunner R, Hamel W, Mehdorn HM, Tonn JC, Hilt D, Westphal M (2004) Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma. J Neurooncol 66:351–360PubMedCrossRef
20.
Zurück zum Zitat Giese A, Westphal M (1996) Glioma invasion in the central nervous system. Neurosurgery 39:235–250PubMedCrossRef Giese A, Westphal M (1996) Glioma invasion in the central nervous system. Neurosurgery 39:235–250PubMedCrossRef
21.
Zurück zum Zitat Gottfried ON, Deogaonkar M, Way DL, Hamilton AJ (2000) Postoperative cerebral edema after intracavitary implantation of Gliadel(R) wafers for treatment of malignant gliomas [abstract]. J Invest Med 48:79 Gottfried ON, Deogaonkar M, Way DL, Hamilton AJ (2000) Postoperative cerebral edema after intracavitary implantation of Gliadel(R) wafers for treatment of malignant gliomas [abstract]. J Invest Med 48:79
22.
Zurück zum Zitat Gururangan S, Cokgor L, Rich JN, Edwards S, Affronti ML, Quinn JA, Herndon JE 2nd, Provenzale JM, McLendon RE, Tourt-Uhlig S, Sampson JH, Stafford-Fox V, Zaknoen S, Early M, Friedman AH, Friedman HS (2001) Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro Oncol 3:246–250PubMedCentralPubMed Gururangan S, Cokgor L, Rich JN, Edwards S, Affronti ML, Quinn JA, Herndon JE 2nd, Provenzale JM, McLendon RE, Tourt-Uhlig S, Sampson JH, Stafford-Fox V, Zaknoen S, Early M, Friedman AH, Friedman HS (2001) Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro Oncol 3:246–250PubMedCentralPubMed
23.
Zurück zum Zitat Gutenberg A, Lumenta CB, Braunsdorf WE, Sabel M, Mehdorn HM, Westphal M, Giese A (2013) The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience. J Neurooncol 113:163–174PubMedCrossRef Gutenberg A, Lumenta CB, Braunsdorf WE, Sabel M, Mehdorn HM, Westphal M, Giese A (2013) The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience. J Neurooncol 113:163–174PubMedCrossRef
24.
Zurück zum Zitat Kleinberg LR, Weingart J, Burger P, Carson K, Grossman SA, Li K, Olivi A, Wharam MD, Brem H (2004) Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management. Cancer Invest 22:1–9PubMedCrossRef Kleinberg LR, Weingart J, Burger P, Carson K, Grossman SA, Li K, Olivi A, Wharam MD, Brem H (2004) Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management. Cancer Invest 22:1–9PubMedCrossRef
25.
Zurück zum Zitat La Rocca RV, Vitaz TW, Villaneuver W, Hodes J, Cervera A, New P, Litofsky NS (2008) A Phase 2 Study of Multimodal Therapy With Surgery, Carmustine (BCNU) Wafer, Radiation, and Temozolomide in Patients With Newly Diagnosed Supratentorial Malignant Glioma. Abstract and poster presented at the 8th Meeting of the European Association of Neurooncology (EANO), September 12–14, Barcelona La Rocca RV, Vitaz TW, Villaneuver W, Hodes J, Cervera A, New P, Litofsky NS (2008) A Phase 2 Study of Multimodal Therapy With Surgery, Carmustine (BCNU) Wafer, Radiation, and Temozolomide in Patients With Newly Diagnosed Supratentorial Malignant Glioma. Abstract and poster presented at the 8th Meeting of the European Association of Neurooncology (EANO), September 12–14, Barcelona
26.
Zurück zum Zitat McGirt MJ, Than KD, Weingart JD, Chaichana KL, Attenello FJ, Olivi A, Laterra J, Kleinberg LR, Grossman SA, Brem H, Quinones-Hinojosa A (2009) Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 110:583–588PubMedCrossRef McGirt MJ, Than KD, Weingart JD, Chaichana KL, Attenello FJ, Olivi A, Laterra J, Kleinberg LR, Grossman SA, Brem H, Quinones-Hinojosa A (2009) Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 110:583–588PubMedCrossRef
27.
Zurück zum Zitat Menei P, Metellus P, Parot-Schinkel E, Loiseau H, Capelle L, Jacquet G, Guyotat J (2010) Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. Ann Surg Oncol 17:1740–1746PubMedCrossRef Menei P, Metellus P, Parot-Schinkel E, Loiseau H, Capelle L, Jacquet G, Guyotat J (2010) Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. Ann Surg Oncol 17:1740–1746PubMedCrossRef
28.
Zurück zum Zitat Mueller S, Polley MY, Lee B, Kunwar S, Pedain C, Wembacher-Schroder E, Mittermeyer S, Westphal M, Sampson JH, Vogelbaum MA, Croteau D, Chang SM (2011) Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. J Neurooncol 101:267–277PubMedCentralPubMedCrossRef Mueller S, Polley MY, Lee B, Kunwar S, Pedain C, Wembacher-Schroder E, Mittermeyer S, Westphal M, Sampson JH, Vogelbaum MA, Croteau D, Chang SM (2011) Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. J Neurooncol 101:267–277PubMedCentralPubMedCrossRef
29.
Zurück zum Zitat National Comprehensive Cancer Network NCCN (2012) Clinical Practice Guidelines in Oncology. Central nervous system cancer. Version 1 National Comprehensive Cancer Network NCCN (2012) Clinical Practice Guidelines in Oncology. Central nervous system cancer. Version 1
30.
Zurück zum Zitat Noel G, Schott R, Froelich S, Gaub MP, Boyer P, Fischer-Lokou D, Dufour P, Kehrli P, Maitrot D (2012) Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior Gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas. Int J Radiat Oncol Biol Phys 82:749–755PubMedCrossRef Noel G, Schott R, Froelich S, Gaub MP, Boyer P, Fischer-Lokou D, Dufour P, Kehrli P, Maitrot D (2012) Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior Gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas. Int J Radiat Oncol Biol Phys 82:749–755PubMedCrossRef
31.
Zurück zum Zitat Pan E, Mitchell SB, Tsai JS (2008) A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. J Neurooncol 88:353–357PubMedCrossRef Pan E, Mitchell SB, Tsai JS (2008) A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. J Neurooncol 88:353–357PubMedCrossRef
32.
Zurück zum Zitat Perry JR, Belanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF (2010) Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 28:2051–2057PubMedCrossRef Perry JR, Belanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF (2010) Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 28:2051–2057PubMedCrossRef
33.
Zurück zum Zitat Sabel M, Giese A (2008) Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. Curr Med Res Opin 24:3239–3257PubMedCrossRef Sabel M, Giese A (2008) Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. Curr Med Res Opin 24:3239–3257PubMedCrossRef
34.
Zurück zum Zitat Salvati M, D'Elia A, Frati A, Brogna C, Santoro A, Delfini R (2011) Safety and feasibility of the adjunct of local chemotherapy with biodegradable carmustine (BCNU) wafers to the standard multimodal approach to high-grade gliomas at first diagnosis. J Neurosurg Sci 55:1–6PubMed Salvati M, D'Elia A, Frati A, Brogna C, Santoro A, Delfini R (2011) Safety and feasibility of the adjunct of local chemotherapy with biodegradable carmustine (BCNU) wafers to the standard multimodal approach to high-grade gliomas at first diagnosis. J Neurosurg Sci 55:1–6PubMed
35.
Zurück zum Zitat Sampath P, Brem H (1998) Implantable slow-release chemotherapeutic polymers for the treatment of malignant brain tumors. Cancer Control 5:130–137PubMed Sampath P, Brem H (1998) Implantable slow-release chemotherapeutic polymers for the treatment of malignant brain tumors. Cancer Control 5:130–137PubMed
36.
Zurück zum Zitat Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401PubMedCrossRef Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401PubMedCrossRef
37.
Zurück zum Zitat Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, Rohde V, Oppel F, Turowski B, Woiciechowsky C, Franz K, Pietsch T (2008) Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62:564–576PubMedCrossRef Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, Rohde V, Oppel F, Turowski B, Woiciechowsky C, Franz K, Pietsch T (2008) Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62:564–576PubMedCrossRef
38.
Zurück zum Zitat Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRef Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRef
39.
Zurück zum Zitat Stupp R, Tonn JC, Brada M, Pentheroudakis G (2010) High-grade malignant glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v190–v193PubMedCrossRef Stupp R, Tonn JC, Brada M, Pentheroudakis G (2010) High-grade malignant glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v190–v193PubMedCrossRef
40.
Zurück zum Zitat Subach BR, Witham TF, Kondziolka D, Lunsford LD, Bozik M, Schiff D (1999) Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. Neurosurgery 45:17–22PubMedCrossRef Subach BR, Witham TF, Kondziolka D, Lunsford LD, Bozik M, Schiff D (1999) Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. Neurosurgery 45:17–22PubMedCrossRef
41.
Zurück zum Zitat Tamargo RJ, Epstein JI, Reinhard CS, Chasin M, Brem H (1989) Brain biocompatibility of a biodegradable, controlled-release polymer in rats. J Biomed Mater Res 23:253–266PubMedCrossRef Tamargo RJ, Epstein JI, Reinhard CS, Chasin M, Brem H (1989) Brain biocompatibility of a biodegradable, controlled-release polymer in rats. J Biomed Mater Res 23:253–266PubMedCrossRef
42.
Zurück zum Zitat Tran B, Rosenthal MA (2010) Survival comparison between glioblastoma multiforme and other incurable cancers. J Clin Neurosci 17:417–421PubMedCrossRef Tran B, Rosenthal MA (2010) Survival comparison between glioblastoma multiforme and other incurable cancers. J Clin Neurosci 17:417–421PubMedCrossRef
43.
Zurück zum Zitat Ulmer S, Spalek K, Nabavi A, Schultka S, Mehdorn HM, Kesari S, Dorner L (2012) Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma. Neuro Oncol 14:482–490PubMedCentralPubMedCrossRef Ulmer S, Spalek K, Nabavi A, Schultka S, Mehdorn HM, Kesari S, Dorner L (2012) Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma. Neuro Oncol 14:482–490PubMedCentralPubMedCrossRef
45.
Zurück zum Zitat Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jaaskelainen J, Ram Z (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5:79–88PubMedCentralPubMed Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jaaskelainen J, Ram Z (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5:79–88PubMedCentralPubMed
46.
Zurück zum Zitat Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, Meyermann R, Reifenberger G, Weller M, Wick W (2007) Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25:3357–3361PubMedCrossRef Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, Meyermann R, Reifenberger G, Weller M, Wick W (2007) Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25:3357–3361PubMedCrossRef
Metadaten
Titel
Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma
verfasst von
Maria Angela Samis Zella
Marta Wallocha
Philipp J. Slotty
Gueler Isik
Daniel Hänggi
Juliane Schroeteler
Christian Ewelt
Hans-Jakob Steiger
Michael Sabel
Publikationsdatum
01.02.2014
Verlag
Springer Vienna
Erschienen in
Acta Neurochirurgica / Ausgabe 2/2014
Print ISSN: 0001-6268
Elektronische ISSN: 0942-0940
DOI
https://doi.org/10.1007/s00701-013-1931-6

Weitere Artikel der Ausgabe 2/2014

Acta Neurochirurgica 2/2014 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.